Targets for lung-directed gene therapy include genetic disorders such as cystic fibrosis (CF) and alpha-1 antitrypsin deficiency, as well as acquired diseases including chronic obstructive pulmonary disease, asthma, lung cancers and others [7, 8]. The gene discussed is SERPINA1; the disease is cystic fibrosis.